title: Human prostate cancer model: roles of growth factors and extracellular matrices.
abstract: A human prostate cancer model was established by inoculating a prostate specific antigen (PSA)-producing LNCaP cell line with either prostate or bone fibroblasts. Alternatively, this human prostate cancer model can also be established by inoculating LNCaP cells with growth factor(s) (GFs) and extracellular matrix (ECM) immobilized on Gelfoam. The resulting LNCaP tumors were used to evaluate PSA production and excretion in athymic hosts. This model was also employed to examine the biochemical nature of mesenchymal cell-derived growth-promoting protein(s) and to assess the efficacy of potential chemotherapeutic agents. Because of the propensity of human prostate cancer to metastasize to the bone, this study defined a 1.0 M NaCl-eluted fraction, MS1, from the conditioned medium of a bone stromal cell line (MS) by heparin-affinity column chromatography. The growth-promoting activity was assayed both in vivo (e.g., tumor formation) and in vitro (e.g., soft agar colony formation). We found that the growth-promoting activity was trypsin- and heat-sensitive, and partially degraded by acid and dithiothreitol. Immunochemical studies indicated that the polyclonal antibody raised against MS1 blocked the growth-promoting effect elicited by the bone-conditioned media. This growth-promoting factor was found to be immunochemically dissimilar to KGF, HGF, and bFGF. However, addition of bFGF, HGF and NGF, but not aFGF, TGF beta, IGF1, IGF2, PDGF, EGF, TGF alpha and KGF, stimulated anchorage-independent growth of prostate cells, a condition closely parallel to tumor formation in vivo. We found that the MS1 fraction also contained fibronectin and tenascin but not laminin or collagen IV.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Department of Urology and Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston 77030.
authors.forename: L W
authors.initials: LW
authors.lastname: Chung
authors.forename: W
authors.initials: W
authors.lastname: Li
authors.forename: M E
authors.initials: ME
authors.lastname: Gleave
authors.forename: J T
authors.initials: JT
authors.lastname: Hsieh
authors.forename: H C
authors.initials: HC
authors.lastname: Wu
authors.forename: R A
authors.initials: RA
authors.lastname: Sikes
authors.forename: H E
authors.initials: HE
authors.lastname: Zhau
authors.forename: M G
authors.initials: MG
authors.lastname: Bandyk
authors.forename: C J
authors.initials: CJ
authors.lastname: Logothetis
authors.forename: J S
authors.initials: JS
authors.lastname: Rubin
mesh_terms: D000818:Animals; D004195:Disease Models, Animal; D016326:Extracellular Matrix Proteins / Q000494:pharmacology / Q000502:physiology*; D006133:Growth Substances / Q000494:pharmacology / Q000502:physiology*; D006801:Humans; D008297:Male; D008954:Models, Biological; D009368:Neoplasm Transplantation; D011471:Prostatic Neoplasms / Q000473:pathology
chemical_list: D016326:Extracellular Matrix Proteins; D006133:Growth Substances